Publications

Books and Chapters

Rathmell, W.K. HIF biology in renal cell carcinoma. In Renal Cell Carcinoma: Biology, Prognostic Factors, and Therapeutic Targets. Eds. Robert Figlin, Brian Rini, and W. Kimryn Rathmell. 2012

Arreola, A. and Rathmell, W.K. Biology of RCC (VEGF, mTOR, immune aspects). In Renal cell carcinoma: clinical management. Eds. Brian Rini and Stephen Campbell. 2012

Li, M. and Rathmell, W.K. Biomarkers in renal cell carcinoma, ASCO Education Book, 2011.

Haake, S. and Rathmell, W.K. The biology of renal cell carcinoma. In Emerging Cancer Therapeutics: Renal Cancer. Eds. Walter Stadler and Jame Abraham. 2011. Pages 1-20.

Li, M. and Rathmell, W.K. Biomarkers for renal cell carcinoma. In Renal cell carcinoma: Principles and Practice. Eds. Primo Lara and Eric Jonasch. 2011.

Oosterwijk, E., Belldegrun, A., Brannon, A.R. Finley, D.S., Junker, K., Pouliot, F., Rathmell, W.K. and Uemura, H. Basic Research in Kidney Cancer. In Kidney Cancer. Eds. Z. Kirkali and P. Mulders. 1st EAU-ICUD International Consultation on Kidney Cancer, Barcelona, 2010. Edition 2011. Pages 31-45

Reddy, A., Kronek, L-P., Brannon, A.R., Seiler, M., Ganesan, S., Rathmell, W.K., Bhanot, G. Predicting Cancer Survival Using Expression Patterns. In Medical Biostatistics for Complex Diseases. Emmert-Streib, F. and Dehmer, M. (eds.). pp. 305-330. 2010

Rini, B.I. and Rathmell, W.K. Vascular Endothelial Growth Factor Ligand-Binding Agents. In Renal Cell Carcinoma, Rini, B. and Campbell, S. (eds.). pp. 203-210, 2009.

Amin, C. and Rathmell, W.K. Angiogenesis Biology in Metastatic Renal Cell Carcinoma. In Renal Cell Carcinoma, Rini, B. and Campbell, S. (eds.). pp. 191-202, 2009.

Rathmell, W.K. and Rini, B.I. Biologic and Clinical Implications of VEGF Activity in Renal Cell Carcinoma. In Renal Cell Carcinoma, Bukowski, R., Motzer, R., and Figlin, R. (eds.). pp. 99-118. 2008.

Rathmell, W.K. and Godley, P. Testicular Cancer. In Netter’s Internal Medicine. 2nd Edition. Runge, M. and Greganti, A. (eds.). pp. 614-622, 2008.

Rathmell, W.K. , Stadler, W.M., Rini, B.I. Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer, ASCO Education Book, 7 typed pages, 2008.

Rathmell, W.K. VHL Gene: Clinical Implications, In ASCO Education Book, pp. 239-244, 2007.

Rathmell, W.K. , Chu, G. Mechanisms for DNA double-strand break repair in eukaryotic cells. In Nickolof, J.A., Hoekstra, M.F. (eds.) DNA damage and repair, Vol. 2: DNA repair in higher eukaryotes, Humana Press, pp. 299-316, 1998

Refereed Papers/Articles, Original Research

Khandani, A., Cowey, C.L., Moore, D.T., Gohil, H., Rathmell, W.K. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. Nuclear Medicine Communication, 2012 Sep;33(9):967-73. PMID: 22714005

Gamper, AM, Qiao, X, Kim, J, Zhang, L, DeSimone, MC, Rathmell, WK, Wan, Y. Regulation of KLF4 turnover reveals an unexpected tissue specific role of pVHL in tumorigenesis. Molecular Cell. 2012 Jan; 45(2):233-43. PMID: 22284679; NIHMS351326.

Brannon, A.R., Haake, S., Hacker, K.E., Pruthi, R.S., Wallen, E.M., Nielsen, M.E., and Rathmell, WK Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol. 2012 Feb;61(2):258-68. PMID: 22030119; PMC3244546

The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Sep 23 [Epub ahead of print] PMID: 23000897. Indexed as Kimryn Rathmell, W.

Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 489(7417):519-25. PMID: 22960745. Indexed as Kimryn Rathmell, W.

Manvar AM, Rathmell WK, Ferguson J, Pruthi RS, Nielsen ME, Wallen EM, Nolan N, Raynor MC. Carcinoma in a Cadaveric Transplant Kidney. Urology 2012 Feb;61(2):258-68. PMID: 22014593

Teng BL, Hacker KE, Chen S, Means AR, Rathmell WK. Tumor Suppressive Activity of Prolyl Isomerase Pin1 in Renal Cell Carcinoma. Mol Oncol. 2011 Oct;5(5):465-74. PMID: 21764651; PMC3194764 *Cover.

Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol. 2011 Mar 9. [Epub ahead of print] PMID: 21470103

Brannon, A.R. *, Reddy, A.*, Seiler, M., Arreola, A., Moore, D.T., Pruthi, R., Wallen, E., Liu, H., Ljungberg, B., Zhao, H., Brooks, J.D., Ganesan, S., Bhanot, G., and Rathmell, W.K. Molecular Stratification of Clear Cell Renal Cell Carcinoma Reveals Distinct Subtypes and Survival Patterns. *Co-first authorship. Genes and Cancer. 2010. 1(2): 152-163. PMID: 20871783; PMC2943630

Bender, AA, Tang, W, Middeldorp, JM, Greijer, AE, Thorne, LB, Funkhouser, WK, Rathmell, WK, Gulley, MA Epstein-Barr Virus Latent Membrane Protein 1 is not Associated with Vessel Density nor with Hypoxia Inducible Factor 1 Alpha Expression in Nasopharyngeal Carcinoma Tissue. Head and Neck Pathology. 3(4):276-82. 2010. PMID: 20871783

Liu, H., Brannon, A.R., Reddy, A., Alexe, G., Seiler, M., Arreola, A., Oza, J., Yao, M., Juan, D., Liou, L., Ganesan, S., Levine, A.J., Rathmell, W.K.*, Bhanot, G.*, Identifying direct mRNA targets of microRNA in clear cell renal cell carcinoma. BMC Systems Biology. 2010 4(1):51*Co-corresponding authors. PMID: 20420713; PMC2876063

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD‐1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010 Sep 15;116(18):4256-65. PMID: 20549832

Chen, S., Sanford, C.A., Sun, J., Choi, V., Van Dyke, T., Samulski, R.J., and Rathmell, W.K. VHL and PTEN loss coordinate to promote liver vascular lesions. Angiogenesis. 2010. 13(1): 59-69. PMID: 20221685

Wright, T.M., Rathmell, W.K. Identification of Ror2 as a hypoxia inducible factor (HIF) target in von Hippel-Lindau (VHL)-associated renal cell carcinoma. Journal of Biological Chemistry. 2010 Apr 23;285(17):12916-24. PMID: 20185829; PMC2857057

Cowey, C.L., Amin, C., Pruthi, R.S., Wallen, E.M., Nielsen, M.E., Grigson, G., Watkins, C., Nance, K.V., Crane, J., Jalkut, M., Kim, W.Y., Godley, P.A., Whang, Y.E., Fielding, J.R., and Rathmell, W.K. A Neoadjuvant Clinical Trial with Sorafenib for Patients with Stage II or Greater Renal Cell Carcinoma. Journal of Clinical Oncology. 2010. 28(9): 1502-7. PMID: 20159822

Pruthi, R.S., Nielsen, M., Heathcote, S., Wallen, E.M., Rathmell, W.K., Godley, P., Whang, Y., Fielding, J., Schultz, H., Grigson, G., Smith, A., Kim, W. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int. 2010 Jan 19. 106(3):349-56. 20089114

Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell W.K., Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA. Neoadjuvant docetaxel/ estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial. Urol. Oncol. 2009. Epub ahead of print. PMID: 20022268

Cowey, C.L., Fielding, J., and Rathmell, W.K. The Loss of Radiographic Enhancement in Primary Renal Cell Carcinoma Tumors Following Multi-targeted Receptor Tyrosine Kinase Therapy is an Additional Indicator of Response. Urology. 2010 May;75(5):1108-13.e1.. PMID: 19931124

Kurpad, R, Kim, W.Y., Rathmell, W.K., Godley, P, Whang, Y., Fielding, J., Smith, L., Pettiford, A., Schultz, H., Nielsen, M., Wallen, E.M., Pruthi, R.S. A multidisciplinary approach to the management of urologic malignancies: Does it influence diagnostic and treatment decisions? Urologic Oncology. 2011 Jul-Aug;29(4):378-82. PMID: 19576797

Wright, T. M., Brannon, A. R., Gordan, J. D., Mikels, A. J., Mitchell, C., Chen, S., Espinosa, I., van de Rijn, M., Pruthi, R., Wallen, E., Edwards, L., Nusse, R., and Rathmell, W. K. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene, 28: 2513-2523, 2009. PMID: 19448672; PMC2771692

Lee, C. M., Hickey, M. M., Sanford, C. A., McGuire, C. G., Cowey, C. L., Simon, M. C., and Rathmell, W. K. VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Oncogene, 28: 1694-1705, 2009. PMID: 19252526; PMC2667565

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 Aug 9;372(9637):449-56. PMID:18653228

Rathmell, W. K. and Monk, J. P. High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review. Urology, 72: 659-663, 2008. PMID: 18649931

Hacker, K. E., Lee, C. M., and Rathmell, W. K. VHL type 2B mutations retain VBC complex form and function. PLoS One, 3: e3801, 2008. PMID: 19030229; PMC2583047

Gordan, J. D., Lal, P., Dondeti, V. R., Letrero, R., Parekh, K. N., Oquendo, C. E., Greenberg, R. A., Flaherty, K. T., Rathmell, W. K., Keith, B., Simon, M. C., and Nathanson, K. L. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell, 14: 435-446, 2008. PMID: 19061835; PMC2621440

Amin, C., Wallen, E., Pruthi, R. S., Calvo, B. F., Godley, P. A., and Rathmell, W. K. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology, 72: 864-868, 2008. PMID: 18684493

Hickey, M. M., Lam, J. C., Bezman, N. A., Rathmell, W. K., and Simon, M. C. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. J Clin Invest, 117: 3879-3889, 2007. PMID: 17992257

Gollob, J. A., Rathmell, W. K., Richmond, T. M., Marino, C. B., Miller, E. K., Grigson, G., Watkins, C., Gu, L., Peterson, B. L., and Wright, J. J. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol, 25: 3288-3295, 2007. PMID: 17664476

Rathmell, W. K. , Malkowicz, S. B., Holroyde, C., Luginbuhl, W., and Vaughn, D. J. Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer. Am J Clin Oncol, 27: 109-112, 2004. PMID: 15057147

Rathmell, W. K. , Hickey, M. M., Bezman, N. A., Chmielecki, C. A., Carraway, N. C., and Simon, M. C. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Res, 64: 8595-8603, 2004. PMID: 15574766

Rathmell, W. K. , Acs, G., Simon, M. C., and Vaughn, D. J. HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma. Anticancer Res, 24: 167-169, 2004. PMID: 15015593

Mack, F. A., Rathmell, W. K., Arsham, A. M., Gnarra, J., Keith, B., and Simon, M. C. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell, 3: 75-88, 2003. PMID: 12559177

Rathmell, W. K ., Arguin, P., Chan, S., and Yu, A. Yersinia pseudotuberculosis bacteremia and splenic abscess in a patient with non-insulin-dependent diabetes mellitus. West J Med, 170: 110-112, 1999. PMID: 10063398

Smider, V., Rathmell, W. K., Brown, G., Lewis, S., and Chu, G. Failure of hairpin-ended and nicked DNA To activate DNA-dependent protein kinase: implications for V(D)J recombination. Mol Cell Biol, 18: 6853-6858, 1998. PMID: 9774698

Rathmell, W. K. , Kaufmann, W. K., Hurt, J. C., Byrd, L. L., and Chu, G. DNA-dependent protein kinase is not required for accumulation of p53 or cell cycle arrest after DNA damage. Cancer Res, 57: 68-74, 1997. PMID: 8988043

Errami, A., Smider, V., Rathmell, W. K., He, D. M., Hendrickson, E. A., Zdzienicka, M. Z., and Chu, G. Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants. Mol Cell Biol, 16: 1519-1526, 1996. PMID: 8657125

Smider, V.*, Rathmell, W. K.*, Lieber, M. R., and Chu, G. Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA. Science, 266: 288-291, 1994. PMID: 7939667 *Co-first authorship.

Rathmell, W. K. and Chu, G. A DNA end-binding factor involved in double-strand break repair and V(D)J recombination. Mol Cell Biol, 14: 4741-4748, 1994. PMID: 7516471

Rathmell, W. K. and Chu, G. Involvement of the Ku autoantigen in the cellular response to DNA double-strand breaks. Proc Natl Acad Sci U S A, 91: 7623-7627, 1994. PMID: 8052631

Wiens, D. J., Mann, T. K., Fedderson, D. E., Rathmell, W. K., and Franck, B. H. Early heart development in the chick embryo: effects of isotretinoin on cell proliferation, alpha-actin synthesis, and development of contractions. Differentiation, 51: 105-112, 1992. PMID: 1473624

Other peer reviewed articles (Reviews)

Jonasch, E., Futreal, P.A., Bailey, S., Kim, W.Y., Atkins, M., Sharma, P., Davis, I.J., Walker, C., Rathmell, W.K. State of the Science: update on renal cell carcinoma. Molecular Cancer Research. 2012 Jul;10(7):859-80. PMID: 22638109; PMC3399969

Khandani AH, Rathmell WK. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. Semin Nucl Med. 2012 Jul;42(4):221-30. PMID: 22681671

Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A Basic Research in Kidney Cancer. Eur Urol. 2011 Oct;60(4):622-33. PMID: 21741760

Rasmussen, N. and Rathmell, W.K. Looking beyond inhibition of VEGF/mTOR: Emerging targets for renal cell carcinoma drug development. Current Clinical Pharmacology. 2011 Aug;6(3):199-206.PMID: 21470103

Hacker, K.E., Rathmell, W.K. Emerging molecular classification in RCC: implications for drug development. Targeted Oncology. 5(2):75-84, 2010. PMID: 20645016

Brannon, A.R., Rathmell, W.K. Renal cell carcinoma, where will the state of the art lead us? Current Oncology Reports. 2010;12(3):193-201 PMID: 20425079

Rathmell, W.K , and Godley, P.A. Updates in Renal Cell Carcinoma. Current Opinion in Oncology. 2010;22(3):250-6. PMID: 20154618

Rathmell, W.K. , Pruthi, R., Wallen, E. Neoadjuvant treatment of renal cell carcinoma. 2010. 28(1):69-73 PMID: 20123351

Rathmell, W.K., Cowey, C.L., and Fielding, J. Reply: Is objective response rate

completely objective in kidney cancer? Improving radiographic assessment of targeted therapy in renal cell carcinoma. Urology, 2009, Nov 18. Epub ahead of print. PMID: 19931124

Cowey, C. L. and Rathmell, W. K. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep, 11: 94-101, 2009. PMID: 19216840

Cowey, C.L. and Rathmell, W.K. Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. Expert Opinion on Drug Discovery 3(3): 311-327, 2008.

Rini, B. I., Rathmell, W. K., and Godley, P. Renal cell carcinoma. Curr Opin Oncol, 20: 300-306, 2008.

Rathmell, W. K. and Chen, S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther, 8: 63-73, 2008. PMID: 18095884

Rini, B. I. and Rathmell, W. K. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin Cancer Res, 13: 741s-746s, 2007. PMID: 17255303

Rathmell, W. K., Martz, C. A., and Rini, B. I. Renal cell carcinoma. Curr Opin Oncol, 19: 234-240, 2007. PMID: 17414642

Rini, B. I., Campbell, S. C., and Rathmell, W. K. Renal cell carcinoma. Curr Opin Oncol, 18: 289-296, 2006. PMID: 16552243

Rathmell, W. K., Wright, T. M., and Rini, B. I. Molecularly targeted therapy in renal cell carcinoma. Expert Rev Anticancer Ther, 5: 1031-1040, 2005. PMID: 16336094

Rathmell, W. K. and Simon, M. C. VHL: oxygen sensing and vasculogenesis. J Thromb Haemost, 3: 2627-2632, 2005. PMID: 15975138

Rathmell, W. K ., Godley, P. A., and Rini, B. I. Renal cell carcinoma. Curr Opin Oncol, 17: 261-267, 2005. PMID: 15818172

Rathmell, W. K. and Godley, P. A. Renal cell carcinoma. Curr Opin Oncol, 16: 247-252, 2004. PMID: 15069321

top